VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The NuQ® tests are based on our Nucleosomics® technology platform, a simple immunoassay based approach to identify and measure epigenetic features of nucleosomes in the bloodstream – an indication that cancer is present.
VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centred in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.
State of Ownership
Managing Director, Thoroughly Good Consulting
Sales Account Executive, Springer Nature
CEO & Co-Founder, Zapnito